adambeyoncelowe
Senior Member (Voting Rights)
There isn't really any evidence to point to in these areas. Without a good understanding of mechanisms its just clustering of reported symptoms and people making guesses over what is important/different.
Well exactly. And there was a very limited amount of time. The debate around names is one we could have forever, but ME/CFS will do for now. It shows NICE is listening. This was always going to be an exercise in compromise, though.
There's a need to be pragmatic. If we'd spent an hour talking about the name, we wouldn't have had time to discuss other things. It was more important to stress that we need objective measures in these clinics, rather than more SF-36-type stuff; that co-morbidities shouldn't be ignored, even if they're not covered in detail in the guideline; that critiques and reanalysis of evidence also needs to be borne in mind; etc.
The key points at our table about criteria were that there needs to be stratification of patients around PEM, and an easy-to-use set of criteria for GPs.
Stratifying with PEM means we can start collecting data, and that will help us make the case in future about taking group x out of the equation or giving them their own guideline distinct from group y. It may actually help us prove, once and for all, if ME patients are distinct from CFS patients and whether they need separate guidelines.
The criteria also have to be easy to follow, so that GPs can start treating patients immediately, rather than delaying treatment for months or (as is more usual) years. They should have the leeway to start some things straight away for any 'suspected' cases.